STRUCTURED ABSTRACT
Objective
We sought to determine the risk of lymphedema associated with immediate breast reconstruction compared to mastectomy alone.
Background
Immediate breast reconstruction is increasingly performed at the time of mastectomy. Few studies have examined whether breast reconstruction impacts development of lymphedema.
Methods
616 breast cancer patients who underwent 891 mastectomies between 2005–2013 were prospectively screened for lymphedema at our institution, with 22.2 months median follow-up. Mastectomies were categorized as immediate implant, immediate autologous, or no reconstruction. Arm measurements were performed pre-operatively and during post-operative follow-up using a Perometer. Lymphedema was defined as ≥10% arm volume increase compared to pre-operative. Kaplan-Meier and Cox regression analyses were performed to determine lymphedema rates and risk factors.
Results
Of 891 mastectomies, 65% (580/891) had immediate implant, 11% (101/891) immediate autologous, and 24% (210/891) no reconstruction. The two-year cumulative incidence of lymphedema was: 4.08% (95% CI: 2.59–6.41%) implant, 9.89% (95% CI: 4.98–19.1%) autologous, and 26.7% (95% CI: 20.4–34.4%) no reconstruction. By multivariate analysis, immediate implant (HR: 0.352, p<0.0001) but not autologous (HR: 0.706, p=0.2151) reconstruction was associated with a significantly reduced risk of lymphedema compared to no reconstruction. Axillary lymph node dissection (p<0.0001), higher Body Mass Index (p<0.0001), and greater number of nodes dissected (p=0.0324) were associated with increased lymphedema risk.
Conclusion
This prospective study suggests that in patients for whom implant-based reconstruction is available, immediate implant reconstruction does not increase the risk of lymphedema compared to mastectomy alone.